J.F.R. Robertson - Concepedia

Author

J.F.R. Robertson

Also Known As

J F R Robertson, J F Robertson, J. F. R. Robertson, J. F. Robertson, J. Robertson, J.F Robertson, J.F. Robertson, J.F.R. ROBERTSON, J.F.R. Robertson, JFR Robertson

123

Publications

4.7K

Citations

H-Index

Concepts

All Affiliations

Nottingham City Hospital University of Nottingham Tenovus Cancer Care Garvan Institute of Medical Research

About

J.F.R. Robertson is an author at Nottingham City Hospital specializing in breast cancer, medicine, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	17	1.3K
2	Cell Biology	4	4	412
3	Health Sciences	3	3	112
4	Endocrinology	3	3	312
5	Engineering	2	2	149

J.F.R. Robertson

Publications

3.9K

Citations

H-Index

Page 1

	Year	Citations
Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. C. Focan, S. M. Steinberg, M Blichert-Toft, PubMed	1998	2.2K
Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer Anthony Howell, D.J. DeFriend, R.W. Blamey, The Lancet Breast OncologyOncologyTamoxifen-resistant Breast CancerMedicinePathology	1995	348
Comparison of the short-term biological effects of 7alpha-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. J.F.R. Robertson, Robert I. Nicholson, NJ Bundred, PubMed Breast OncologyVersus TamoxifenGynecologyPrimary Breast CancerShort-term Biological Effects	2001	216
Screening interval breast cancers: mammographic features and prognosis factors. H.C. Burrell, D.M. Sibbering, A.R.M. Wilson, Radiology	1996	193
Pathological prognostic factors in breast cancer. IV: Should you be a typer or a grader? A comparative study of two histological prognostic features in operable breast carcinoma H. Pereira, S Pinder, D.M. Sibbering, Histopathology	1995	177
Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy SG Archer, Aristides G. Eliopoulos, Demetrios�� Spandidos, British Journal of Cancer Advanced Breast CancerBreast OncologyEndocrine-related CancerMedicineCancer Growth	1995	163
INK4a gene expression and methylation in primary breast cancer: overexpression of p16INK4a messenger RNA is a marker of poor prognosis. Rina Hui, R D Macmillan, F S Kenny, PubMed Breast OncologyEngineeringCyclin D1Estrogen ReceptorCancer Biology	2000	120
Cyclin D1 and estrogen receptor messenger RNA levels are positively correlated in primary breast cancer. Rina Hui, Ann L. Cornish, R A McClelland, PubMed Er Gene ExpressionBreast OncologyCyclin D1Estrogen ReceptorPathology	1996	76
The clinical relevance of static disease (no change) category for 6 months on endocrine therapy in patients with breast cancer J.F.R. Robertson, Peter C. Willsher, Kwok‐Leung Cheung, European Journal of Cancer Breast OncologyMedicineClinical RelevanceGynecologyStatic Disease	1997	64
A randomised trial of primary tamoxifen versus mastectomy plus adjuvant tamoxifen in fit elderly women with invasive breast carcinoma of high oestrogen receptor content: long-term results at 20 years of follow-up Simon J. Johnston, F.S. Kenny, Binafsha Manzoor Syed, Annals of Oncology Breast OncologyMedicineRandomised TrialGynecologyBreast Cancer	2012	56

Page 1